Guobang Pharma (SH:605507) Sou Hu Cai Jing·2025-07-29 12:27Financial Performance - The company achieved operating revenue of 3.026 billion yuan, an increase of 4.63% compared to the same period last year [1][2] - The net profit attributable to shareholders was 455.57 million yuan, reflecting a growth of 12.60% year-on-year [1][3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 436.03 million yuan, up by 10.33% from the previous year [1][3] - The total profit for the period was 521.31 million yuan, compared to 464.09 million yuan in the same period last year [3] Cash Flow and Assets - The net cash flow from operating activities was 102.88 million yuan, a significant improvement from a negative cash flow of 249.98 million yuan in the previous year [3] - The net assets attributable to shareholders at the end of the reporting period were 8.057 billion yuan, slightly up from 8.047 billion yuan at the end of the previous year [3] - Total assets amounted to 10.808 billion yuan, compared to 10.780 billion yuan at the end of the previous year [3] Investment Activities - The company announced a partnership to establish a private equity investment fund, with a total commitment of 50 million yuan, where the company will contribute 10 million yuan, accounting for 20% of the fund [4] - The fund will focus on investing in companies aligned with national strategic emerging industries and future industry development directions [4] - The partnership has been officially registered with the China Securities Investment Fund Industry Association [4] Business Overview - The company operates in the pharmaceutical manufacturing sector, focusing on human medicine, animal health products, plant health, and food-drug homology [3] - It serves a global market, distributing products to 117 countries and regions across six continents, with over 5,000 supply partners including major pharmaceutical companies like Bayer, Eli Lilly, Abbott, and Novartis [3]